Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Y Look

Showing results (51-60 of 58) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 58 results.
Cancer|May 1, 1999
Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1J A Hurteau, B Allison, G P Sutton, et al.
Gynecologic Oncology|January 27, 1998
A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgeryJ M Schilder, J A Hurteau, K Y Look, et al.
The New England Journal of Medicine|January 4, 1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|February 1, 1997
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|October 1, 1996
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)W P McGuire, W J Hoskins, M F Brady, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Gynecologic Oncology|December 1, 1996
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group studyK Y Look, V L Brunetto, D L Clarke-Pearson, et al.
Gynecologic Oncology|October 1, 1992
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomasK Y Look, G P Sutton, Y Natsumeda, et al.
Pageof 6

Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Cancer|May 1, 1999
Transforming growth factor-beta differentially inhibits epithelial ovarian carcinoma cells from primary and metastatic isolates without up-regulation of p21WAF1J A Hurteau, B Allison, G P Sutton, et al.
Gynecologic Oncology|January 27, 1998
A prospective controlled trial of early postoperative oral intake following major abdominal gynecologic surgeryJ M Schilder, J A Hurteau, K Y Look, et al.
The New England Journal of Medicine|January 4, 1996
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|February 1, 1997
Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: a Gynecologic Oncology Group studyW P McGuire, W J Hoskins, M F Brady, et al.
Seminars in Oncology|October 1, 1996
Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group)W P McGuire, W J Hoskins, M F Brady, et al.
American Journal of Clinical Oncology|February 24, 2001
Phase I trial of paclitaxel and etoposide for recurrent ovarian carcinoma: a Gynecologic Oncology Group StudyG F Fleming, B J Roth, S D Baker, et al.
Gynecologic Oncology|December 1, 1996
An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group studyK Y Look, V L Brunetto, D L Clarke-Pearson, et al.
Gynecologic Oncology|October 1, 1992
Inhibition by tiazofurin of inosine 5'-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomasK Y Look, G P Sutton, Y Natsumeda, et al.
Pageof 6